Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tazobactam Sodium

FDA-approved product (injectable, injection).

Registered studies
14
Lab records
23
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Tazobactam Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Appendicitis
  • Bacterial disease
  • Cellulitis
  • Diabetic foot
  • Endometritis
  • Infection
  • Pelvic Inflammatory Disease
  • Peritonitis
  • Pneumonia
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta-lactamase inhibitors
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CG02

Repurposing investigation

Tazobactam Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA78.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli85.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae69.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis10.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

14registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 2 of 2 lab records
  • E. coli: measured active in 8 of 11 lab records
  • K. pneumoniae: measured active in 4 of 6 lab records
  • M. tuberculosis: measured active in 0 of 4 lab records
Open Tazobactam Sodium in ChEMBL Registered studies below
Show the 23 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tazobactam Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation

    NCT07759453 · start 2026-10-01

    Registered record
    Registry ID
    NCT07759453
    Conditions
    Liver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization
    Interventions
    Ceftazidime - Avibactam ( CAZ-AVI); Meropenem-Vaborbactam; Imipenem+Relebactam; Cefiderocol; Aztreonam; Eravacycline; Aztreonam-Avibactam; Amoxi Clavulanate; Piperacillin + Tazobactam; Tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2029-09-30
    Enrolment
    168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization
    InterventionCeftazidime - Avibactam ( CAZ-AVI); Meropenem-Vaborbactam; Imipenem+Relebactam; Cefiderocol +6 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment

    NCT07481539 · start 2026-03-24

    Registered record
    Registry ID
    NCT07481539
    Conditions
    Bacteria Infection; Piperacillin, Tazobactam Drug Combination
    Interventions
    Piperacillin, Tazobactam Drug Combination; Piperacillin, Tazobactam Drug Combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-03-24
    Completion
    2027-04-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteria Infection; Piperacillin, Tazobactam Drug Combination
    InterventionPiperacillin, Tazobactam Drug Combination; Piperacillin, Tazobactam Drug Combination
    PhasePhase 2
    Registry statusRecruiting

  • A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia

    NCT06972537 · start 2024-07-24

    Registered record
    Registry ID
    NCT06972537
    Conditions
    Pneumonia
    Interventions
    Increase the frequency and extended infusion time of Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda) 4.5g; Extended Infusion Time of Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda), 4.5g
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-07-24
    Completion
    2026-09-30
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionIncrease the frequency and extended infusion time of Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda) 4.5g; Extended Infusion Time of Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda), 4.5g
    PhaseNot applicable
    Registry statusRecruiting

  • Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis

    NCT06035055 · start 2023-10

    Registered record
    Registry ID
    NCT06035055
    Conditions
    Bronchiectasis; Cystic Fibrosis; Pseudomonas Aeruginosa; Burkholderia Cepacia Infection
    Interventions
    Ceftolozane/tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-10
    Completion
    2024-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchiectasis; Cystic Fibrosis; Pseudomonas Aeruginosa; Burkholderia Cepacia Infection
    InterventionCeftolozane/tazobactam
    PhasePhase 4
    Registry statusUnknown

  • Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations

    NCT06076200 · start 2023-09-30

    Registered record
    Registry ID
    NCT06076200
    Conditions
    Early-Onset Neonatal Sepsis
    Interventions
    Piperacillin Sodium and Tazobactam Sodium for Injection
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-09-30
    Completion
    2026-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly-Onset Neonatal Sepsis
    InterventionPiperacillin Sodium and Tazobactam Sodium for Injection
    PhaseNot recorded
    Registry statusRecruiting

  • Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis.

    NCT05981079 · start 2023-07-31

    Registered record
    Registry ID
    NCT05981079
    Conditions
    Late-Onset Neonatal Sepsis
    Interventions
    Piperacillin/tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-07-31
    Completion
    2025-05-31
    Enrolment
    332

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLate-Onset Neonatal Sepsis
    InterventionPiperacillin/tazobactam
    PhasePhase 4
    Registry statusUnknown

  • Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

    NCT04673175 · start 2023-01-10

    Registered record
    Registry ID
    NCT04673175
    Conditions
    Pneumonia; Hematologic Malignancy; Pseudomonas Aeruginosa Infection; Bacteremia; Hematopoietic Stem Cell Transplant (HSCT)
    Interventions
    Ceftolozane / Tazobactam Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-01-10
    Completion
    2025-03-16
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; Hematologic Malignancy; Pseudomonas Aeruginosa Infection; Bacteremia +1 more
    InterventionCeftolozane / Tazobactam Injection
    PhasePhase 4
    Registry statusTerminated

  • Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections

    NCT05060419 · start 2021-10-08

    Registered record
    Registry ID
    NCT05060419
    Conditions
    Complicated Urinary Tract Infection; Acute Pyelonephritis
    Interventions
    Meropenem- FL058; Piperacillin -tazobactam; Saline; Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-10-08
    Completion
    2022-08-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection; Acute Pyelonephritis
    InterventionMeropenem- FL058; Piperacillin -tazobactam; Saline; Saline
    PhasePhase 2
    Registry statusUnknown

  • Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

    NCT02166476 · start 2014-11-20

    Registered record
    Registry ID
    NCT02166476
    Conditions
    Urinary Tract Infection Complicated; Acute Pyelonephritis
    Interventions
    Meropenem-Vaborbactam; Piperacillin-Tazobactam; Levofloxacin; Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-11-20
    Completion
    2016-04-28
    Enrolment
    550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection Complicated; Acute Pyelonephritis
    InterventionMeropenem-Vaborbactam; Piperacillin-Tazobactam; Levofloxacin; Saline
    PhasePhase 3
    Registry statusCompleted

  • Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)

    NCT01370616 · start 2011-09-02

    Registered record
    Registry ID
    NCT01370616
    Conditions
    Infection; Diabetic Foot
    Interventions
    Ertapenem sodium; Piperacillin/tazobactam sodium; Piperacillin/tazobactam-matching placebo; Amoxicillin/clavulunate potassium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09-02
    Completion
    2013-12-18
    Enrolment
    565

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection; Diabetic Foot
    InterventionErtapenem sodium; Piperacillin/tazobactam sodium; Piperacillin/tazobactam-matching placebo; Amoxicillin/clavulunate potassium
    PhasePhase 3
    Registry statusCompleted

  • Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

    NCT00634166 · start 2007-09

    Registered record
    Registry ID
    NCT00634166
    Conditions
    Burns
    Interventions
    Sulfamylon® For 5 % Topical Solution; Topical Antimicrobial/Antifungal Medications
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2007-09
    Completion
    2014-04
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurns
    InterventionSulfamylon® For 5 % Topical Solution; Topical Antimicrobial/Antifungal Medications
    PhasePhase 4
    Registry statusTerminated

  • Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)

    NCT00389987 · start 2001-09

    Registered record
    Registry ID
    NCT00389987
    Conditions
    Complicated Intra-Abdominal Infections
    Interventions
    MK0826, /Duration of Treatment : 8 Weeks; Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-09
    Completion
    2004-05
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Intra-Abdominal Infections
    InterventionMK0826, /Duration of Treatment : 8 Weeks; Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks
    PhasePhase 3
    Registry statusCompleted

  • Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034)

    NCT00229112 · start 2001-04

    Registered record
    Registry ID
    NCT00229112
    Conditions
    Foot Infections in Diabetic Patients
    Interventions
    MK0826, ertapenem sodium / Duration of Treatment - 24 weeks; Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-04
    Completion
    2004-04
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFoot Infections in Diabetic Patients
    InterventionMK0826, ertapenem sodium / Duration of Treatment - 24 weeks; Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks
    PhasePhase 3
    Registry statusCompleted

  • Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

    NCT00003805 · start 1997-11

    Registered record
    Registry ID
    NCT00003805
    Conditions
    Bone Marrow Suppression; Fever, Sweats, and Hot Flashes; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions
    piperacillin sodium; piperacillin-tazobactam; tazobactam sodium; vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-11
    Completion
    Not recorded
    Enrolment
    859

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Marrow Suppression; Fever, Sweats, and Hot Flashes; Infection; Leukemia +5 more
    Interventionpiperacillin sodium; piperacillin-tazobactam; tazobactam sodium; vancomycin
    PhasePhase 3
    Registry statusCompleted